Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ.

N Engl J Med. 2012 May 31;366(22):2051-3. doi: 10.1056/NEJMp1202623. Epub 2012 May 9. No abstract available.

2.

Bisphosphonates for osteoporosis--where do we go from here?

Whitaker M, Guo J, Kehoe T, Benson G.

N Engl J Med. 2012 May 31;366(22):2048-51. doi: 10.1056/NEJMp1202619. Epub 2012 May 9. No abstract available.

3.

[Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate].

Shiraishi A.

Nihon Yakurigaku Zasshi. 2014 Jun;143(6):302-9. Review. Japanese. No abstract available.

PMID:
24919557
4.

Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.

Tanaka M, Mori H, Shimizu K, Toshiyuki, Matsuoka, Yamamotoya H, Minamide T, Mori M, Nozaki K, Usui T, Shimokawa K, Suzuki H, Aoyama K, Kimoto A, Sasamata M, Miyata K.

Nihon Yakurigaku Zasshi. 2009 Sep;134(3):149-57. Review. No abstract available.

PMID:
19749488
5.

Zoledronic acid: a review of its use in the treatment of osteoporosis.

Deeks ED, Perry CM.

Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007. Review.

PMID:
18947264
6.

[New bone density conservation agents for osteoporosis under research and development: Ibandronate].

Tanaka I, Hashimoto J, Oshima H.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:426-32. Review. Japanese. No abstract available.

PMID:
18161144
7.

Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.

Hochberg MC.

Curr Osteoporos Rep. 2008 Sep;6(3):89-94. Review.

PMID:
18752769
8.

[When should bisphosphonate treatment be discontinued?].

Eriksen EF, Halse J.

Tidsskr Nor Laegeforen. 2012 Aug 7;132(14):1630-2. doi: 10.4045/tidsskr.11.0788. Norwegian. No abstract available.

9.

Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome.

Galli-Tsinopoulou A, Kyrgios I, Giza S, Giannopoulou EZ, Maggana I, Laliotis N.

Minerva Endocrinol. 2012 Sep;37(3):283-9.

PMID:
22766895
10.

[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].

Geusens PP, Lems WF.

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1445-8. Dutch.

PMID:
17633971
11.

[Osteoporosis priority: Reduce the number of fractures].

Roux C.

Presse Med. 2006 Oct;35(10 Pt 2):1527-8. French. No abstract available.

PMID:
17028516
12.

A review of minodronic acid hydrate for the treatment of osteoporosis.

Tanishima S, Morio Y.

Clin Interv Aging. 2013;8:185-9. doi: 10.2147/CIA.S23927. Epub 2013 Feb 15. Review.

13.

Osteoporosis: how long should we treat?

Sebba A.

Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):502-7. doi: 10.1097/MED.0b013e328317ca83. Review.

PMID:
18971678
14.

A once-yearly IV bisphosphonate for osteoporosis.

[No authors listed]

Med Lett Drugs Ther. 2007 Nov 5;49(1273):89-90. No abstract available.

PMID:
17975523
15.

Bisphosphonates.

McClung M.

Arq Bras Endocrinol Metabol. 2006 Aug;50(4):735-44. Review.

16.

[Ibandronate].

Tobinai M.

Clin Calcium. 2011 Jan;21(1):79-86. doi: CliCa11017986. Review. Japanese.

PMID:
21187598
17.

Bone diseases. Incident fractures during treatment for osteoporosis.

Vestergaard P.

Nat Rev Rheumatol. 2013 Sep;9(9):508-10. doi: 10.1038/nrrheum.2013.122. Epub 2013 Aug 13.

PMID:
23938864
18.

Bisphosphonates: forever or 5 years and stop?

Kolber MR, Sadowski CA, Korownyk C.

Can Fam Physician. 2015 May;61(5):443. No abstract available.

19.

[Osteoporosis: Optimizing treatment strategy].

Thomas T.

Presse Med. 2006 Oct;35(10 Pt 2):1543-6. Review. French.

PMID:
17028519
20.

[Treatment of primary osteoporosis in men].

Yamaguchi T, Sugimoto T.

Clin Calcium. 2006 Mar;16(3):474-9. Review. Japanese.

PMID:
16508131
Items per page

Supplemental Content

Write to the Help Desk